Company intelligence / Profile preview

Cenyx Biotech, Inc.

Seoul, Korea Republic/South Koreacenyxbiotech.com ↗

Ownership: Private
Development stage: Other

Overview

Cenyx Biotech is advancing a first-in-class cerium oxide-based nanozyme, CX213, for SAH-induced inflammation. The candidate has received FDA IND approval and orphan drug designation. Phase I trials are set to begin in the US with expedited regulatory strategies targeting commercialization by ~2028. Preclinical data show superior ROS-scavenging ability compared to existing products. A second asset, CX301 for AKI, is approaching IND submission/approval by mid-to-late 2025. Several additional programs remain confidential.

Therapeutic areas: ImmunologyNephrologyNeurology
Modalities: Nanozymes (cerium oxide-based and non-CeO2 nanozymes)
Industry: Biotech

Drug pipeline

4 assets

CX213

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Merck/MSD (discussions)Johnson & Johnson (discussions)Ipsen (discussions)

Beyond the preview

Go deeper on Cenyx Biotech, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cenyx Biotech, Inc..

Explore the full profile